» Articles » PMID: 11553569

Induction of Immune Response in BALB/c Mice with a DNA Vaccine Encoding Bacterioferritin or P39 of Brucella Spp

Overview
Journal Infect Immun
Date 2001 Sep 13
PMID 11553569
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

In this study, we evaluated the ability of DNA vaccines encoding the bacterioferritin (BFR) or P39 proteins of Brucella spp. to induce cellular and humoral immune responses and to protect BALB/c mice against a challenge with B. abortus 544. We constructed eukaryotic expression vectors called pCIBFR and pCIP39, encoding BFR or P39 antigens, respectively, and we verified that these proteins were produced after transfection of COS-7 cells. PCIBFR or pCIP39 was injected intramuscularly three times, at 3-week intervals. pCIP39 induced higher antibody responses than did the DNA vector encoding BFR. Both vectors elicited a T-cell-proliferative response and also induced a strong gamma interferon production upon restimulation with either the specific antigens or Brucella extract. In this report, we also demonstrate that animals immunized with these plasmids elicited a strong and long-lived memory immune response which persisted at least 3 months after the third vaccination. Furthermore, pCIBFR and pCIP39 induced a typical T-helper 1-dominated immune response in mice, as determined by cytokine or immunoglobulin G isotype analysis. The pCIP39 delivered by intramuscular injection (but not the pCIBFR or control vectors) induced a moderate protection in BALB/c mice challenged with B. abortus 544 compared to that observed in positive control mice vaccinated with S19.

Citing Articles

LDH as an adjuvant makes outer-membrane vesicles and outer-membrane vesicle-associated proteins highly protective in mice.

Deng X, He J, Xu J, Wang Y, Yi J, Zhang H Iran J Basic Med Sci. 2023; 26(5):564-571.

PMID: 37051103 PMC: 10083835. DOI: 10.22038/IJBMS.2023.67394.14775.


Proteomics of Brucella.

Poetsch A, Marchesini M Proteomes. 2020; 8(2).

PMID: 32331335 PMC: 7355872. DOI: 10.3390/proteomes8020008.


Identification of Cross-Protective Potential Antigens against Pathogenic spp. through Combining Pan-Genome Analysis with Reverse Vaccinology.

Hisham Y, Ashhab Y J Immunol Res. 2019; 2018:1474517.

PMID: 30622973 PMC: 6304850. DOI: 10.1155/2018/1474517.


Development of new generation of vaccines for .

Gheibi A, Khanahmad H, Kashfi K, Sarmadi M, Khorramizadeh M Heliyon. 2019; 4(12):e01079.

PMID: 30603712 PMC: 6307385. DOI: 10.1016/j.heliyon.2018.e01079.


Intradermal active full-length DNA Aβ42 immunization via electroporation leads to high anti-Aβ antibody levels in wild-type mice.

Rosenberg R, Fu M, Lambracht-Washington D J Neuroimmunol. 2018; 322:15-25.

PMID: 29958693 PMC: 6192700. DOI: 10.1016/j.jneuroim.2018.05.017.


References
1.
Weynants V, Gilson D, Cloeckaert A, Denoel P, Tibor A, Thiange P . Characterization of a monoclonal antibody specific for Brucella smooth lipopolysaccharide and development of a competitive enzyme-linked immunosorbent assay to improve the serological diagnosis of brucellosis. Clin Diagn Lab Immunol. 1996; 3(3):309-14. PMC: 170338. DOI: 10.1128/cdli.3.3.309-314.1996. View

2.
Klinman D, Verthelyi D, Takeshita F, Ishii K . Immune recognition of foreign DNA: a cure for bioterrorism?. Immunity. 1999; 11(2):123-9. DOI: 10.1016/s1074-7613(00)80087-4. View

3.
Tanghe A, DSouza S, Rosseels V, Denis O, Ottenhoff T, Dalemans W . Improved immunogenicity and protective efficacy of a tuberculosis DNA vaccine encoding Ag85 by protein boosting. Infect Immun. 2001; 69(5):3041-7. PMC: 98258. DOI: 10.1128/IAI.69.5.3041-3047.2001. View

4.
Al-Mariri A, Tibor A, Mertens P, De Bolle X, Michel P, Godefroid J . Protection of BALB/c mice against Brucella abortus 544 challenge by vaccination with bacterioferritin or P39 recombinant proteins with CpG oligodeoxynucleotides as adjuvant. Infect Immun. 2001; 69(8):4816-22. PMC: 98569. DOI: 10.1128/IAI.69.8.4816-4822.2001. View

5.
Fensterbank R, PLOMMET M . Vaccination against bovine brucellosis with a low dose of strain 19 administered by the conjunctival route. IV. Comparison between two methods of vaccination. Ann Rech Vet. 1979; 10(1):131-9. View